An interventional study of rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun in Metabolic Syndrome, sponsored by Hamdard University. Recruiting at 1 site in Pakistan. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-23.
Sponsored by Hamdard University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Metabolic Syndrome with a site in Pakistan — 6 open to participants now, 7 under way, none of them phase 3. Metabolic Syndrome · Pakistan.
Among the 16 studies in Metabolic Syndrome with a site in Pakistan, this one is the 3rd largest by planned enrollment, is one of 3 that started in 2023, is one of 14 with no phase, and was the 9th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →6 of the 16 studies in Metabolic Syndrome with a site in Pakistan are open now. Recruiting first, the newest first:
University of Veterinary and Animal Sciences, Lahore - Pakistan · Sites in Pakistan
Ages 18–45
University of Veterinary and Animal Sciences, Lahore - Pakistan · Sites in Pakistan
Ages 35–50
Asif Ali · Sites in Pakistan
Ages 30–60
University of Veterinary and Animal Sciences, Lahore - Pakistan · Sites in Pakistan
Ages 35–55
University of Lahore · Sites in Pakistan
Ages 18–60
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 35 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2
First in 2005; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 60 across the 16 interventional studies. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 16 have an industry lead sponsor. The 9 most frequent:
Hamdard University is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Hamdard University has 1 study filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Metabolic Syndrome with a site in Pakistan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Metabolic syndrome is an important global public health problem and comprises a group of complex risk factors, including obesity, dyslipidemia, hyperglycemia, and hypertension. One of the main diagnostic components of metabolic syndrome is obesity, which is usually measured by the waist circumference and the intra-abdominal visceral fat, in addition to dyslipidemia (the condition of raised triglycerides and reduced high density lipoprotein (HDL)-cholesterol in blood; other components are raised blood pressure and fasting plasma glucose, all of which are related to weight gain.
Metabolic syndrome is related to cardio metabolic risk factors and lipid disorders. Worldwide, cardiovascular diseases (CVD) are the leading cause of mortality and morbidity. It is expected that by 2030, mortality from CVD will reach 22.5 million people, compared with 17.5 million deaths in 2012.
Major pharmacological interventions include management of dyslipidemia with statins, decreasing prothrombotic risk with antiplatelet drugs, and the use of insulin sensitizers to decrease the risk of diabetes. In addition to non-pharmacologic interventions that improve BP, pharmacological agents provide the primary basis for hypertension management in the majority of patients. Among major antihypertensive agents, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), and thiazide (or thiazide-like) diuretics are preferentially recommended in the general condition because of their additional cardiovascular protection effects and/or accessibility.
Herbal drugs are being used worldwide in the management of metabolic syndrome now a days. Some of the herbs e.g. Terminalia arjuna, Trigonella Foenum-graecum, Allium Sativum, Cinnamon verum and Zingiber Officinale are being used very effectively in managing metabolic syndrome.
METHODOLOGY:
The basic purpose of this study will be to explore a poly herbal combination for effective and safe management of metabolic syndrome. This is a multicenter; prospective study will be conducted in the department of Pharmacology, HCMD in collaboration with Hamdard University Hospital, National Medical Center and Amna Unani Hospital.
After fulfilling the inclusion and exclusion criteria a total of 200 patients will be enrolled and divided in 2 groups. One group will be given allopathic combination while the other group will be given a poly herbal formulation. Important parameters include BMI, Systolic and Diastolic blood pressure, lipid profile, HbA1c, S.creatinine, Urinary Albumin, Urinary Creatinine, ALT \& AST. Follow up will be done at day 0, 30, 60 \& 90th of treatment. The data will be recorded in a tabulated form and statistical analysis will be done at the end of the study to see the significance of the two studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1. Tablet.Rosuvastatin 10mg once daily for 3 months 2. Tablet. Telmisartan 40mg once daily for 3 months 3. Tablet. Sitagliptin / Metformin 50/500mg once daily for 3 months
Drug: rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun
1. Cinammon powder 2 gm once daily for 3 months 2. Garlic powder 1 gm once daily for 3 months 3. Ginger powder 4 gm once daily for 3 months 4. Fenugreek powder 10 gm once daily for 3 months 5. Arjuna 2 gm once daily for 3 months
Drug: rosuvastatin, METFORMIN, Sitagliptin, Telmisartan, Cinnamon. garlic, Ginger, Methi dana, Arjun
Comparing allopathic and herbal group of drugs for metabolic syndrome
Glycosylated hemoglobin
at day 0 and day 90
Time frame: 3 months
Systolic blood pressure, diastolic blood pressure
at day 0, day 30, day 60 and day 90
Time frame: 3 months
triglyceride level
at day 0, day 30, day 60 and day 90
Time frame: 3 months
high density lipoprotein level
at day 0, day 30, day 60 and day 90
Time frame: 3 months
waist hip ratio
at day 0 and day 90
Time frame: 3 months
Fasting blood sugar, random blood sugar
at day 0, day 30, day 60 and day 90
Time frame: 3 months
serum cholesterol level
at day 0, day 30, day 60 and day 90
Time frame: 3 months
serum creatinine level
at day 0, day 30, day 60 and day 90
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Jul 2024, 10 months after the start.
Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 10 months is below that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hamdard University